Abstract

Aims: The ultrasonographic (US) evaluation of the median nerve at the level of the carpal tunnel outlet (CTO) and mid forearm in pediatric patients with mucopolysaccharidosis type II (MPS II) and comparison with healthy subjects. Material and method: Fifteen children with MPS II and 44 healthy children were included in the study and they were divided into three age groups. The cross-sectional area, the appearance of the nerve, and the ratio of the cross-sectional areas were evaluated by US. Results: At the level of the CTO the mean area of the nerve was increased in all MPS II groups compared with the correspondent healthy age groups and the differences were statistically significant (p<0.01). At the level of the mid forearm the differences were statistically significant only for the first age group. Other US findings at the level of the CTO in the MPS II groups were represented by hypoechogenicity (86.67 % on the right and 93.33% on the left), thickened fascicles (80% bilaterally), irregular contour (53.33% bilaterally) and the presence of the Doppler signal including the nerve (26.67 % on the right and 33.33 % on the left). The CTO/mid forearm cross-sectional area ratio was higher in all MPS II age groups and the differences were statistically significant (p<0.001). Conclusion: In patients with MPS II there are significant US changes in the size and aspect of the median nerve.

Keywords: mucopolysaccharidosis, median nerve, carpal tunnel outlet, mid forearm, ultrasonography

Introduction

Mucopolysaccharidoses (MPS) represent a group of rare inherited metabolic disorders caused by genetic defects that result in the absence or severe deficiency of one of the lysosomal hydrolases responsible for the degradation of glycosaminoglycans (GAGs) [1,2]. With the exception of MPS II (known as Hunter syndrome), which is an X-linked recessive disease, other lysosomal storage disorders are autosomal-recessive diseases [3]. MPS II occurs almost exclusively in males, but it has also been reported in a small group of female patients. The most common mechanism for disease expression in female patients is thought to involve the process of X-chromosome inactivation [4].

MPS II is caused by a deficiency of iduronate-2-sulfatase, which normally cleaves a sulfate group from GAGs, heparan and dermatan sulfate. A shortage of this enzyme leads to an accumulation of undegraded GAGs within the lysosomes of various tissues, resulting in dysfunction of multiple organs and systems, producing a broad spectrum of chronic and progressive clinical manifestations with significant variability in age of onset and rate of progression [3,5]. In patients with early progressive disease, central nervous system involvement, progressive airway disease, and cardiac disease are present. In those with slowly progressive disease, the central nervous system is not (or is minimally) affected. Additional findings in both forms of MPS II include: short
stature, macrocephaly, macroglossia, hoarse voice, conductive and sensorineural hearing loss, hepatosplenomegaly, hernia, dysostosis multiplex, spinal stenosis, or carpal tunnel syndrome (CTS) [6].

Patients with Hunter syndrome often undergo surgical procedures at a younger age, before diagnosis, so Hunter syndrome should be suspected in young children with a history of surgical interventions, particularly for hernia or CTS [7].

The few studies that have been made reveal a high frequency of the CTS in patients with MPS [8,9]. The diagnosis is usually established based on the clinical exam or nerve conduction studies. However, in MPS the diagnosis may be delayed, as the presentation is commonly atypical. Many patients do not complain of numbness or pain, particularly early in the course of disease when verbal or intellectual limitations may pose additional challenges to the diagnosis [10].

Numerous recent papers have shown similar sensitivity and specificity of ultrasonography (US) and nerve conduction studies in the diagnosis of the CTS [11-17] but no study regarding the US examination of the median nerve in children with Hunter syndrome has been published.

The main objective of our study was to evaluate by US the median nerve in pediatric patients with MPS II and to compare the aspect with the findings of a healthy population. A secondary objective of the study consisted of the assessment of the median nerve US appearance at the level of the carpal tunnel outlet (CTO) and mid forearm in healthy pediatric patients of various age groups since there are no studies published to date regarding this issue according to the authors’ knowledge.

Material and method

The study group consisted of 15 male patients with MPS II, aged between 3 years and 6 months old and 16 years and 9 months old. These are all the pediatric patients diagnosed with MPS II in Romania and they are in the evidence of the Genetics Department of the Emergency Children Hospital, Cluj-Napoca. The mean age of symptoms onset in our study group was 1.78 years (±0.79), the mean age at specific diagnosis was 4.68 years (±2.63) and the mean duration of enzyme replacement therapy was 2.26 years (±1.53). At the moment all patients included in the study are under enzyme replacement therapy. The excluding criteria were represented by other possible causes for CTS and previous surgery for CTS.

The control group consisted of 44 healthy boys, ages between 3 years and 5 months old and 17 years and 6 months old. These children were examined during the same period of time as the MPS II patients. The excluding criteria were: trauma or surgery involving the median nerve and other diseases that might involve or alter the appearance of the median nerve.

All the subjects, both MPS II and control group, were divided into three age groups according to the main developmental stages of childhood: pre-school age group - 3 to 7 years old (mean age 4.7±0.8 and 5.08±1.22, respectively), school age group - 7 to 13 years old (mean age 9.12±2.46 and 10.56±2.12, respectively), and puberty age group - 13 to 17 years old (mean age 15.13±1.25 and 15.78±1.21, respectively), each of the groups presenting specific developmental features. [18]. No statistically significant differences were present concerning the mean age between the groups (all p<0.05).

All the examinations were performed on a Toshiba Xario V 2.0. US machine, using a linear probe, with frequencies ranging from 8 to 14 MHz. For the evaluation of the median nerve the US machine was preset at 14 MHz when examining the CTO and at 8 MHz when examining the median nerve at mid forearm. For vascularisation assessment we used Power Doppler mode interrogation (PRF 0.4-0.6 kHz).

The patients (from both groups) were placed with the forearm in a supine position and the wrist in a neutral position. The transducer was first placed in a transverse view at the level of the CTO, using the pisiform bone as a landmark, and then it was rotated 90° in order to obtain the longitudinal view [19]. The cross-sectional area of the nerve was determined on the transverse image, using the trace area system of the US machine. The examiner traced the outline of the nerve inside the hyperechoic ring produced by the perineurium [20]. In the mid forearm the measurement was also performed on the transverse image in an identical manner. The patients were evaluated by two experimented sonographers, each performing three measurements at each of the four levels and providing the mean value as the final area. The ratio between the CTO and mid forearm areas was also determined.

The nerve was also analyzed qualitatively: echogenicity, aspect of the nerve fascicles, contour, and vascularization (present or absent), bilaterally in CTO and mid forearm, in both transverse and longitudinal view.

The examination of MPS patients and healthy children was performed after written informed consent of the parents or legal guardians was obtained and the study was conducted with the approval of the local Ethics Committee.

Statistical analysis

Databases for healthy children and MPS II patients were realized using Excel. The descriptive statistics was performed in Epi Info 7 and XLStat 2007. The results
were expressed as a mean±standard deviation (SD). Indicators for central tendency and the t dispersion distribution were used to describe the patients and the t test was used for comparison with the healthy children. A value of p<0.05 was considered to be statistically significant.

The agreement between the two examiners which performed the US exams was assessed by using Cohen's Kappa coefficient. For the qualitative evaluation each parameter was considered separately for each of the 15 patients. The coefficient was determined only for the CTO since the measurements of the nerve at the mid forearm were identical.

**Results**

A total of 15 patients with MPS II and 44 healthy children of similar ages were included in the study.

The mean area of the median nerve at the level of the CTO was increased bilaterally in all MPS II patients groups as compared with the healthy groups (all p<0.01). At the level of the mid forearm the differences between the MPS II patients and the healthy subjects was statistically significant only in the first group of age (p<0.01) (Table I).

The ratios between the CTO and mid forearm areas are presented in Table II.

The US qualitative assessment of the median nerve in MPS patients revealed the following alterations at the level of the CTO: hypoechogenicity (86.67 % on the right and 93.33 % on the left, respectively), thickened fascicles (80% bilaterally), irregular contour (53.33 % bilaterally), and the presence of Power Doppler signal (26.67 % on the right and 33.33 % on the left, respectively). Similar findings were present at mid forearm, but the proportion of affected nerves was lower: hypoechogenicity in 6.7 % of the nerves on both sides, thickened fascicles in 20 % on the right and in 13.3 % on the left, irregular contour 13.3 % on both sides and no Power Doppler signal on either side. These US findings, in contrast with the normal aspect, are illustrated in figures 1 and 2.

The analysis of the agreement between the two sonographers in determining the cross-sectional area revealed a very good interobserver agreement (k=0.916).

**Discussions**

The CTS is the most frequent compressive peripheral neuropathy in adults [21,22], but in children it is a very rare entity, most often associated with lysosomal storage disease, and especially with MPS [23-25]. Studies that have already been published about the CTS in MPS II revealed a frequency of the syndrome as high as 96 % [9].

At the moment there are no established guidelines for the diagnosis and treatment of CTS associated with MPS II. The diagnosis is usually made based on clinical signs

### Table I. Comparison between median nerve cross-sectional areas of MPS II patients and healthy subjects groups measured at the level of the carpal tunnel outlet and mid forearm.

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Group 1 Healthy</th>
<th>Group 1 MPS II</th>
<th>Group 2 Healthy</th>
<th>Group 2 MPS II</th>
<th>Group 3 Healthy</th>
<th>Group 3 MPS II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right CTO area (mm²)</td>
<td>4.5±0.97</td>
<td>10.5±4.63</td>
<td>5.56±0.63</td>
<td>17.25±4.03</td>
<td>9.42±1.78</td>
<td>23.67±13.5</td>
</tr>
<tr>
<td>T and p</td>
<td>5.075; p&lt;0.001</td>
<td>11.997; p&lt;0.001</td>
<td>5.44±0.81</td>
<td>18±2.83</td>
<td>8.75±1.91</td>
<td>20±6.93</td>
</tr>
<tr>
<td>Left CTO area (mm²)</td>
<td>4.62±1.02</td>
<td>10.88±4.67</td>
<td>5.221; p&lt;0.001</td>
<td>16.323; p&lt;0.001</td>
<td>5.383; p&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Right MF area (mm²)</td>
<td>3.44±0.51</td>
<td>4.88±1.55</td>
<td>4.31±0.79</td>
<td>5±0.82</td>
<td>7±0.95</td>
<td>9±3.61</td>
</tr>
<tr>
<td>T and p</td>
<td>3.419; p&lt;0.01</td>
<td>1.548; p&gt;0.10</td>
<td>3.461; p&lt;0.01</td>
<td>1.331; p&gt;0.10</td>
<td>2.506; p&lt;0.05</td>
<td></td>
</tr>
</tbody>
</table>

The results are expressed as mean area ± SD. Group 1 - 3 to 7 years old; Group 2 - 7 to 13 years old; Group 3 - 13 to 17 years old; CTO – carpal tunnel outlet; MF – mid forearm;

### Table II. Comparison of the carpal tunnel outlet /mid forearm ratios between healthy subjects and MPS II patients.

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Group 1 Healthy</th>
<th>Group 1 MPS II</th>
<th>Group 2 Healthy</th>
<th>Group 2 MPS II</th>
<th>Group 3 Healthy</th>
<th>Group 3 MPS II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right CTO/MF areas ratio</td>
<td>1.3±0.15</td>
<td>2.32±1.29</td>
<td>1.32±0.23</td>
<td>3.45±0.64</td>
<td>1.35±0.18</td>
<td>2.49±0.55</td>
</tr>
<tr>
<td>T and p</td>
<td>3.208; p&lt;0.02</td>
<td>11.426; p&lt;0.001</td>
<td>3.45±0.64</td>
<td>1.34±0.23</td>
<td>2.13±0.23</td>
<td>5.416; p&lt;0.001</td>
</tr>
<tr>
<td>Left CTO/MF areas ratio</td>
<td>1.27±0.25</td>
<td>2.13±0.83</td>
<td>1.21±0.27</td>
<td>3.45±0.64</td>
<td>1.34±0.23</td>
<td>2.13±0.23</td>
</tr>
<tr>
<td>T and p</td>
<td>3.865; p&lt;0.001</td>
<td>11.220; p&lt;0.001</td>
<td>3.45±0.64</td>
<td>1.34±0.23</td>
<td>2.13±0.23</td>
<td>5.416; p&lt;0.001</td>
</tr>
</tbody>
</table>

The results are expressed as mean area ± SD. Group 1 - 3 to 7 years old; Group 2 - 7 to 13 years old; Group 3 - 13 to 17 years old; CTO – carpal tunnel outlet; MF – mid forearm; SD – standard error
in association with nerve conduction studies. While the clinical signs described by the adults with CTS are well known and frequent, they can be very subtle or missing in children with MPS: decreased sweating, night time waking, gnawing of the hands, or manual clumsiness [26]. Also, these symptoms may be overlooked due to other specific alterations seen in MPS II, such as skeletal dysplasia or articular pain. Also some of the children are either too small or present significant neurological impairment, which prevents them from accurately communicating their symptoms.

The electrophysiological examination is very useful in the diagnosis and evaluation of the severity of the CTS, but may be difficult to be performed in children with MPS II and it must be adapted to the clinical characteristics of the patients [26].

More and more studies have proven that US is an accurate, low cost imaging method that can be used in the evaluation of the CTO anatomy and that is more easily accepted by parents and patients. The US findings associated with the CTS have been described in adults and they consist of the increased size of the median nerve proximal to the flexors retinaculum, sudden change in size at the level of the tunnel outlet, decreased echogenicity, decreased mobility and increase of the Doppler signal [27,28]. According to the knowledge of the authors no studies regarding the US evaluation of the median nerve in MPS II patients have been published. There is a case report of an adult MPS II patient with end-stage CTS published by Alkhachroum et al which reveals the same US findings and acknowledges the role of US in identifying the median nerve and its alterations associated with CTS in MPS II patients. [29]

A meta-analysis found that the sensitivity and specificity of US in establishing the CTS diagnosis in adults, is 77.6% and 86.8 %, respectively [30].

The results of our study correlate with literature regarding the type of changes found in CTS in adults. Obviously, due to the rather small number of patients examined, further studies are necessary, especially multi-centric studies, due to the small number of patients that can be found in a single center.

The values of the cross-sectional area of the median nerve proximal to the carpal tunnel outlet that are considered pathological are different depending on the examiner and the inclusion or not of the epineurium in the measurement. As Klauser et al demonstrated, the measurement of the median nerve cross-sectional area in two different sites and the calculation of the differences between the two sites increases the accuracy of the CTA diagnosis [31]. According to this idea it has been suggested that the ratio between the cross-sectional area of the median nerve at the level of the CTO and the forearm may be a more precise indicator in establishing the diagnosis [32,33]. Hobson-Webb et al found that the cross-sectional area ratio in patients with CTS is higher (2.1±0.5) than in asymptomatic patients (1.0±0.1), a 1.4 ratio having a 100% sensitivity for the detection of CTS patients, while using just the cross-sectional area of the nerve at the level of the carpal tunnel outlet has 45-93% sensitivity, depending on the reference value which was used [32]. We found a significantly higher ratio in healthy subjects than in MPS II patients, while the variation coefficient and the lower standard deviation compared with the wrist measurements may suggest that the CTO – mid forearm ratio is superior in assessing the alterations of the nerve size in MPS II.

Intraneuronal vascularity has been proposed as an additional parameter in the diagnosis of CTS, sometimes
being the only detectable finding [34,35]. Recent studies have shown that endoneural hypervascularity is correlating with the severity of the median nerve lesions evaluated through electrophysiologic studies [36,37]. Dalmau Serra et al demonstrated the recovery from CTS of a MPS II patient after enzyme replacement therapy was introduced [38]. In our study group the Doppler signal was present in only a few patients and this finding could be explained by the fact that almost all of them were under enzyme replacement therapy for various lengths of time. Of course this hypothesis requires further studies also.

Regarding the development of the CTS in MPS II patients there have been only a few hypotheses formulated: the compression of the nerve caused by the thickening of the flexors retinaculum and of the tissue surrounding the tendons sheath due to abundant accumulation of GAGs, or the significant alteration of the local anatomy caused by the bone dysplasia [23,39,40]. The presence of statistically significant changes in the median nerve at the level of the forearm may suggest that the structural changes are, also, caused by the disease itself, and it is not just the compression inducing the changes at the level of the carpal tunnel outlet. Since the histopathological exam is difficult to perform due to ethical issues, further studies will be necessary to confirm these hypotheses.

Our opinion is that in MPS II patients the median nerve area determined by US could be useful for monitoring the response to the treatment (enzyme replacement therapy). In order to do this objectively a US scoring system that will include quantifiable findings (cross-sectional area, hypoechogenicity, thickened fascicles, irregular contour, and presence of Power Doppler signal) needs to be defined in the future.

Our study has some limitations. Since MPS II is a rare disease, the number of patients included in our study is obviously small and that lead to a reduced number of median nerves available for evaluation. Another inconvenience was represented by the fact that the patients had been diagnosed and treated for various periods of time and they present different forms of the disease, leading to a rather heterogeneous group. Nevertheless, we believe that the significant median nerve alterations found in the majority of the MPS II patients in our group overcome these limitations and further studies, maybe multicentric, will be able to establish more accurately the role of US in the diagnosis and monitoring of the MPS II patients.

Conclusions

US is an imaging method that may be considered as a first line investigation in the assessment of the median nerve in MPS II patients as it produces highly accurate results in detecting nerve alterations (increased size, hypoechogenicity, thickened fascicles, irregular contour and presence of Power Doppler signal) associated with MPS II. The CTO/mid forearm cross sectional areas ratio is significantly higher in patients with MPS II than in normal subjects and it seems it is superior in the appreciation of the size of the median nerve in patients with MPS II, promising to be a valid method of the CTS diagnosis.

Conflict of interest: none

References


